
Annual report 2024
added 12-27-2025
OrganiGram Holdings EPS Ratio 2011-2026 | OGI
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -0.51 | -0.789 | -0.068 | 0.17 | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.17 | -0.789 | -0.299 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 4.06 | 4.1 % | $ 57.1 M | ||
|
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | ||
|
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
-1.62 | $ 5.63 | 1.53 % | $ 2.05 B | ||
|
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.35 | 0.86 % | $ 309 M | ||
|
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.19 | -2.87 % | $ 128 M | ||
|
Pacira BioSciences
PCRX
|
-2.15 | $ 24.51 | -3.35 % | $ 1.13 B | ||
|
Harrow Health
HROW
|
-0.14 | $ 39.7 | 2.45 % | $ 1.46 B | ||
|
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 1.14 | -36.67 % | $ 1.41 M | ||
|
Tilray
TLRY
|
-2.35 | $ 6.75 | -2.74 % | $ 4.17 B | ||
|
Evolus
EOLS
|
-0.8 | $ 5.3 | -0.19 % | $ 342 M | ||
|
Sundial Growers
SNDL
|
-1.1 | $ 1.51 | -1.31 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
-14.8 | $ 8.03 | -0.74 % | $ 411 M | ||
|
Veru
VERU
|
-0.28 | $ 2.32 | 0.43 % | $ 313 M | ||
|
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | ||
|
Viatris
VTRS
|
0.05 | $ 14.59 | -1.08 % | $ 17.5 B | ||
|
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
-1.79 | $ 1.01 | - | $ 4.36 M | ||
|
Assertio Holdings
ASRT
|
-4.74 | $ 18.04 | 0.11 % | $ 116 M | ||
|
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
-1.99 | $ 7.92 | -3.65 % | $ 693 M | ||
|
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.21 | -0.55 % | $ 285 M | ||
|
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-0.17 | $ 1.02 | -2.86 % | $ 50.9 M | ||
|
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | ||
|
Aurora Cannabis
ACB
|
-4.1 | $ 3.39 | 3.35 % | $ 86.3 M | ||
|
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-0.15 | $ 0.87 | 1.99 % | $ 31.3 M | ||
|
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-0.74 | $ 0.61 | 1.65 % | $ 2.62 M | ||
|
TherapeuticsMD
TXMD
|
-0.05 | $ 2.19 | 0.46 % | $ 25.3 M |